{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:38:10Z","timestamp":1793871490752,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jgar.2025.05.014","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T23:37:10Z","timestamp":1747352230000},"page":"337-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Clinical, microbiological, and laboratory predictors of on- and off-label dalbavancin treatment failure"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-0703","authenticated-orcid":false,"given":"Maria","family":"Mazzitelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-1505","authenticated-orcid":false,"given":"Daniele","family":"Mengato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta Maria Vittoria","family":"Giunco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6389-887X","authenticated-orcid":false,"given":"Elena","family":"Barzizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Salmaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0396-4377","authenticated-orcid":false,"given":"Francesca","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.05.014_bib0001","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2025.05.014_bib0002","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.014_bib0003","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.014_bib0004","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.05.014_bib0005","first-page":"11:1377","article-title":"Off-label use of dalbavancin for sequential treatment of spondylodiscitis by methicillin-resistant Staphylococcus aureus: a retrospective single-centre experience","author":"Mazzitelli","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.05.014_bib0006","first-page":"e495","article-title":"Population pharmacokinetic and pharmacodynamic analysis of dalbavancin for long-term treatment of subacute and\/or chronic infectious diseases: the major role of therapeutic drug monitoring","volume":"11","author":"Cojutti","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.05.014_bib0007","doi-asserted-by":"crossref","first-page":"dlad044","DOI":"10.1093\/jacamr\/dlad044","article-title":"Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals","volume":"5","author":"Bai","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.05.014_bib0008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s15010-024-02393-9","article-title":"A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis","volume":"53","author":"Leanza","year":"2025","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2025.05.014_bib0009","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial","volume":"9","author":"McCarthy","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2025.05.014_bib0010","first-page":"13","article-title":"The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI","volume":"11","author":"Carbonara","year":"2024","journal-title":"Glob Reg Health Technol Assess"},{"key":"10.1016\/j.jgar.2025.05.014_bib0011","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jgar.2024.06.002","article-title":"Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry","volume":"38","author":"Zhanel","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2025.05.014_bib0012","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2106\/00004623-199504000-00010","article-title":"Long-term intravenous therapy with use of peripherally inserted silicone-elastomer catheters in orthopaedic patients","volume":"77","author":"Parker","year":"1995","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.jgar.2025.05.014_bib0013","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jiac.2021.12.022","article-title":"Clinical failure of dalbavancin for MRSA bacteremia in patient with severe obesity and history of IVDU","volume":"28","author":"Ritchie","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2025.05.014_bib0014","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC guidelines for the management of endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jgar.2025.05.014_bib0015","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s15010-024-02176-2","article-title":"In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a national registry","volume":"52","author":"Esposito","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2025.05.014_bib0016","doi-asserted-by":"crossref","first-page":"ofab212","DOI":"10.1093\/ofid\/ofab212","article-title":"Effect of obesity on clinical failure of patients treated with beta-lactams","volume":"8","author":"Pinner","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.014_bib0017","doi-asserted-by":"crossref","first-page":"ofx102","DOI":"10.1093\/ofid\/ofx102","article-title":"Risk factors associated with outpatient parenteral antibiotic therapy program failure among intravenous drug users","volume":"4","author":"Buehrle","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.014_bib0018","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.21037\/jtd-20-1897","article-title":"Type 2 diabetes is associated with failure of non-operative treatment for sternoclavicular joint infection","volume":"12","author":"Reddy","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jgar.2025.05.014_bib0019","doi-asserted-by":"crossref","first-page":"ofz396","DOI":"10.1093\/ofid\/ofz396","article-title":"Recurrent endocarditis in persons who inject drugs","volume":"6","author":"Rodger","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.014_bib0020","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2022.03.349","article-title":"Diagnosis and management of infective endocarditis in people who inject drugs: JACC State-of-the-art review","volume":"79","author":"Yucel","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jgar.2025.05.014_bib0021","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.idc.2020.06.004","article-title":"Infective endocarditis in persons who use drugs: epidemiology, current management, and emerging treatments","volume":"34","author":"Schranz","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jgar.2025.05.014_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpdd.695","article-title":"Dalbavancin population pharmacokinetic modeling and target attainment analysis","volume":"9","author":"Carrothers","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jgar.2025.05.014_bib0023","doi-asserted-by":"crossref","first-page":"ofad256","DOI":"10.1093\/ofid\/ofad256","article-title":"Dalbavancin for the treatment of acute bacterial skin and skin structure infection in patients with obesity or diabetes: a subgroup analysis of pooled phase 3 clinical trials","volume":"10","author":"Riccobene","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.014_bib0024","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.clinthera.2016.07.094","article-title":"Anti-infective dosing for obese adult patients: a focus on newer drugs to treat methicillin-resistant Staphylococcus aureus acute bacterial skin and skin structure infections","volume":"38","author":"Pai","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2025.05.014_bib0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.014_bib0026","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1093\/ofid\/ofx163.114","article-title":"Efficacy and safety of Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in the obese population","volume":"4","author":"Georgiades","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.05.014_bib0027","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12866-019-1596-2","article-title":"Microbial biofilm correlates with an increased antibiotic tolerance and poor therapeutic outcome in infective endocarditis","volume":"19","author":"Di Domenico","year":"2019","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jgar.2025.05.014_bib0028","first-page":"14:1882","article-title":"Clinical effectiveness and pharmacokinetics of dalbavancin in treatment-experienced patients with skin, osteoarticular, or vascular infections","author":"Stroffolini","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525001171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:19:46Z","timestamp":1750868386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525001171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"alternative-id":["S2213716525001171"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.05.014","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical, microbiological, and laboratory predictors of on- and off-label dalbavancin treatment failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}